Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acusphere, Inc.
Acusphere, Inc. Reports Q3 2008 Financial Results and Business Highlights
November 28th, 2008
Acusphere, Inc. (NASDAQ: ACUS) reported financial results for the third quarter ended September 30, 2008 and commented on its financial results and business highlights. Recent Developments Following the close of the third quarter, Acusphere announced a definitive agreement with Cephalon, Inc. to provide Acusphere with $20.0 million in upfront financing through the issuance of a $15.0 million senior secured convertible note and a $5.0 million upfront fee for an exclusive worldwide license to AI-525, a preclinical-stage injectable formulation of celecoxib using Acusphere's proprietary Hydrophobic Drug Delivery System (HDDS(TM)) technology. The...
Source: Health Business Week (2008-11-28)
|
